133 related articles for article (PubMed ID: 31093708)
1. Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis.
Strati P; Abdelrahim M; Selamet U; Page VD; Pierce SA; Verstovsek S; Abudayyeh A
Ann Hematol; 2019 Jul; 98(7):1611-1616. PubMed ID: 31093708
[TBL] [Abstract][Full Text] [Related]
2. Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts.
Passamonti F; Maffioli M; Cervantes F; Vannucchi AM; Morra E; Barbui T; Caramazza D; Pieri L; Rumi E; Gisslinger H; Knoops L; Kiladjian JJ; Mora B; Hollaender N; Pascutto C; Harrison C; Cazzola M
Blood; 2014 Mar; 123(12):1833-5. PubMed ID: 24443442
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data.
Palandri F; Breccia M; Tiribelli M; Bonifacio M; Benevolo G; Iurlo A; Elli EM; Binotto G; Tieghi A; Polverelli N; Martino B; Abruzzese E; Bergamaschi M; Heidel FH; Cavazzini F; Crugnola M; Bosi C; Isidori A; Auteri G; Forte D; Latagliata R; Griguolo D; Cattaneo D; Trawinska M; Bartoletti D; Krampera M; Semenzato G; Lemoli RM; Cuneo A; Di Raimondo F; Vianelli N; Cavo M; Palumbo GA
Hematol Oncol; 2020 Aug; 38(3):372-380. PubMed ID: 32271957
[TBL] [Abstract][Full Text] [Related]
4. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.
Vannucchi AM; Kantarjian HM; Kiladjian JJ; Gotlib J; Cervantes F; Mesa RA; Sarlis NJ; Peng W; Sandor V; Gopalakrishna P; Hmissi A; Stalbovskaya V; Gupta V; Harrison C; Verstovsek S;
Haematologica; 2015 Sep; 100(9):1139-45. PubMed ID: 26069290
[TBL] [Abstract][Full Text] [Related]
5. Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis.
Mascarenhas J; Mehra M; He J; Potluri R; Loefgren C
J Med Econ; 2020 Jul; 23(7):721-727. PubMed ID: 32159402
[No Abstract] [Full Text] [Related]
6. Trends in overall mortality among US veterans with primary myelofibrosis.
Tashi T; Yu J; Pandya S; Dieyi C; Scherber R; Parasuraman S
BMC Cancer; 2023 Jan; 23(1):48. PubMed ID: 36641455
[TBL] [Abstract][Full Text] [Related]
7. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.
Harrison CN; Vannucchi AM; Kiladjian JJ; Al-Ali HK; Gisslinger H; Knoops L; Cervantes F; Jones MM; Sun K; McQuitty M; Stalbovskaya V; Gopalakrishna P; Barbui T
Leukemia; 2016 Aug; 30(8):1701-7. PubMed ID: 27211272
[TBL] [Abstract][Full Text] [Related]
8. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.
Cervantes F; Vannucchi AM; Kiladjian JJ; Al-Ali HK; Sirulnik A; Stalbovskaya V; McQuitty M; Hunter DS; Levy RS; Passamonti F; Barbui T; Barosi G; Harrison CN; Knoops L; Gisslinger H;
Blood; 2013 Dec; 122(25):4047-53. PubMed ID: 24174625
[TBL] [Abstract][Full Text] [Related]
9. Survival outcomes in myelofibrosis patients treated with ruxolitinib: A population-based cohort study in Sweden and Norway.
Schain F; Vago E; Song C; He J; Liwing J; Löfgren C; Björkholm M
Eur J Haematol; 2019 Dec; 103(6):614-619. PubMed ID: 31536656
[TBL] [Abstract][Full Text] [Related]
10. Risk of mortality and second malignancies in primary myelofibrosis before and after ruxolitinib approval.
Thomas JW; Jamy O; Shah MV; Vachhani P; Go RS; Goyal G
Leuk Res; 2022 Jan; 112():106770. PubMed ID: 34920340
[TBL] [Abstract][Full Text] [Related]
11. Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib.
Breccia M; Bartoletti D; Bonifacio M; Palumbo GA; Polverelli N; Abruzzese E; Bergamaschi M; Tieghi A; Tiribelli M; Iurlo A; Cavazzini F; Sgherza N; Binotto G; Isidori A; D'Adda M; Crugnola M; Bosi C; Heidel F; Molica M; Scaffidi L; Cattaneo D; Latagliata R; Auteri G; Lemoli RM; Fanin R; Russo D; Aversa F; Cuneo A; Semenzato G; Catani L; Cavo M; Vianelli N; Foà R; Palandri F
Ann Hematol; 2019 Apr; 98(4):889-896. PubMed ID: 30515542
[TBL] [Abstract][Full Text] [Related]
12. Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.
Palandri F; Breccia M; Bonifacio M; Polverelli N; Elli EM; Benevolo G; Tiribelli M; Abruzzese E; Iurlo A; Heidel FH; Bergamaschi M; Tieghi A; Crugnola M; Cavazzini F; Binotto G; Isidori A; Sgherza N; Bosi C; Martino B; Latagliata R; Auteri G; Scaffidi L; Griguolo D; Trawinska M; Cattaneo D; Catani L; Krampera M; Lemoli RM; Cuneo A; Semenzato G; Foà R; Di Raimondo F; Bartoletti D; Cavo M; Palumbo GA; Vianelli N
Cancer; 2020 Mar; 126(6):1243-1252. PubMed ID: 31860137
[TBL] [Abstract][Full Text] [Related]
13. Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis.
Pugliese N; Giordano C; Nappi D; Luciano L; Cerchione C; Annunziata M; Casale B; Crisà E; Villa MR; Pezzullo L; Iovine M; Picardi M; Grimaldi F; Pane F; Martinelli V
Cancer Med; 2019 Jun; 8(6):2802-2809. PubMed ID: 30997748
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
Verstovsek S; Mesa RA; Gotlib J; Gupta V; DiPersio JF; Catalano JV; Deininger MW; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner EO; Lyons RM; Paquette R; Raza A; Jones M; Kornacki D; Sun K; Kantarjian H;
J Hematol Oncol; 2017 Feb; 10(1):55. PubMed ID: 28228106
[TBL] [Abstract][Full Text] [Related]
15. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
[TBL] [Abstract][Full Text] [Related]
16. Fatal Disseminated Tuberculosis during Treatment with Ruxolitinib Plus Prednisolone in a Patient with Primary Myelofibrosis: A Case Report and Review of the Literature.
Tsukamoto Y; Kiyasu J; Tsuda M; Ikeda M; Shiratsuchi M; Ogawa Y; Yufu Y
Intern Med; 2018 May; 57(9):1297-1300. PubMed ID: 29279479
[TBL] [Abstract][Full Text] [Related]
17. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.
Verstovsek S; Gotlib J; Mesa RA; Vannucchi AM; Kiladjian JJ; Cervantes F; Harrison CN; Paquette R; Sun W; Naim A; Langmuir P; Dong T; Gopalakrishna P; Gupta V
J Hematol Oncol; 2017 Sep; 10(1):156. PubMed ID: 28962635
[TBL] [Abstract][Full Text] [Related]
18. SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.
Mesa RA; Kiladjian JJ; Catalano JV; Devos T; Egyed M; Hellmann A; McLornan D; Shimoda K; Winton EF; Deng W; Dubowy RL; Maltzman JD; Cervantes F; Gotlib J
J Clin Oncol; 2017 Dec; 35(34):3844-3850. PubMed ID: 28930494
[TBL] [Abstract][Full Text] [Related]
19. Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN.
Breccia M; Andriani A; Montanaro M; Abruzzese E; Buccisano F; Cedrone M; Centra A; Villivà N; Celesti F; Trawinska MM; Massaro F; Di Veroli A; Anaclerico B; Colafigli G; Molica M; Spadea A; Petriccione L; Cimino G; Latagliata R
Ann Hematol; 2017 Mar; 96(3):387-391. PubMed ID: 27889820
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.
Verstovsek S; Mesa RA; Gotlib J; Levy RS; Gupta V; DiPersio JF; Catalano JV; Deininger MW; Miller CB; Silver RT; Talpaz M; Winton EF; Harvey JH; Arcasoy MO; Hexner EO; Lyons RM; Raza A; Vaddi K; Sun W; Peng W; Sandor V; Kantarjian H;
Haematologica; 2015 Apr; 100(4):479-88. PubMed ID: 25616577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]